Background: AMD is becoming one of the leading causes of blindness in older adults.
The prevalence rate of the wet form of AMD has been increasing due to the lack of selective
therapeutic modalities. Current therapeutic interventions such as drugs targeting VEGF, and
VEGF receptors, laser coagulants delivered unsuccessful clinical outcomes in AMD patients.
Hence, the cost-effective anti-oxidant therapeutic interventions like molecular hydrogen to protect
retinal pigment epithelium (RPE) by mitigating oxidative stress may deliver effective clinical
outcomes in AMD patients.
Methods: Female patients with late-stage AMD of age above 70 years were chosen for this case
report. The patients were administered QIAPI1©, a melanin precursor via sublingual route and the
photographs were obtained for left and right eye to depict the efficacy of QIAPI1© against the
wet form of AMD.
Results: The administration of QIAPI1© extensively mitigated yellow-colored drusen accumulations
in the retina, retinal edema, exudates, and hemorrhages in the right eye, but the effect was
minimal in the case of left eye; the overall drusen accumulation was lesser than the first consultation.
Conclusion: Current case report has concluded the intrinsic effect of melanin in producing the
molecular hydrogen and chemical energy across the retinal tissues by dissociating water molecules
and dissipating the drusen accumulations, retinal edema, and hemorrhages in AMD patients.
Our preliminary study reported the usage of QIAPI1© as a prospective therapeutic modality
to mitigate the oxidative stress-mediated pathophysiology of the wet form of AMD.